Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults - PubMed (original) (raw)
Review
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults
G Vernon et al. Aliment Pharmacol Ther. 2011 Aug.
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease, and its worldwide prevalence continues to increase with the growing obesity epidemic. This study assesses the epidemiology of NAFLD in adults based on clinical literature published over the past 30 years.
Aim: To review epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults based on clinical literature published over the past 30 years.
Methods: An in-depth search of PubMed (1980-2010) was based on five search terms: 'non-alcoholic fatty liver disease' OR 'non-alcoholic steatohepatitis' OR 'fatty liver' OR 'steatosis' AND 'incidence' [MeSH Terms] OR 'prevalence' [MeSH Terms] OR 'natural history'. Studies of paediatric cohorts were excluded. Articles were categorised by topic and summarised, noting generalisations concerning their content.
Results: Four study categories included NAFLD incidence, prevalence, risk factors and natural history. Studies related to NAFLD prevalence and incidence indicate that the diagnosis is heterogeneous and relies on a variety of assessment tools, including liver biopsy, radiological tests such as ultrasonography, and blood testing such as liver enzymes. The prevalence of NAFLD is highest in populations with pre-existing metabolic conditions such as obesity and type II diabetes. Many studies investigating the natural history of NAFLD verify the progression from NASH to advanced fibrosis and hepatocellular carcinoma.
Conclusions: Non-alcoholic fatty liver disease is the most common cause of elevated liver enzymes. Within the NAFLD spectrum, only NASH progresses to cirrhosis and hepatocellular carcinoma. With the growing epidemic of obesity, the prevalence and impact of NAFLD continues to increase, making NASH potentially the most common cause of advanced liver disease in coming decades.
© 2011 Blackwell Publishing Ltd.
Similar articles
- Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD).
Bellentani S, Marino M. Bellentani S, et al. Ann Hepatol. 2009;8 Suppl 1:S4-8. Ann Hepatol. 2009. PMID: 19381118 Review. - Characteristics and diagnosis of NAFLD/NASH.
Hashimoto E, Taniai M, Tokushige K. Hashimoto E, et al. J Gastroenterol Hepatol. 2013 Dec;28 Suppl 4:64-70. doi: 10.1111/jgh.12271. J Gastroenterol Hepatol. 2013. PMID: 24251707 Review. - Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Younossi ZM. Younossi ZM. Aliment Pharmacol Ther. 2008 Jul;28(1):2-12. doi: 10.1111/j.1365-2036.2008.03710.x. Epub 2008 Apr 11. Aliment Pharmacol Ther. 2008. PMID: 18410557 Review. - Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S, Razavi H. Estes C, et al. J Hepatol. 2018 Oct;69(4):896-904. doi: 10.1016/j.jhep.2018.05.036. Epub 2018 Jun 8. J Hepatol. 2018. PMID: 29886156 - Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
Xu ZJ, Shi JP, Yu DR, Zhu LJ, Jia JD, Fan JG. Xu ZJ, et al. Adv Ther. 2016 Nov;33(11):2069-2081. doi: 10.1007/s12325-016-0416-4. Epub 2016 Oct 14. Adv Ther. 2016. PMID: 27743352
Cited by
- Long Working Hours and Risk of Nonalcoholic Fatty Liver Disease: Korea National Health and Nutrition Examination Survey VII.
Song E, Kim JA, Roh E, Yu JH, Kim NH, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi KM. Song E, et al. Front Endocrinol (Lausanne). 2021 May 6;12:647459. doi: 10.3389/fendo.2021.647459. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34025577 Free PMC article. - Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation.
Wree A, Johnson CD, Font-Burgada J, Eguchi A, Povero D, Karin M, Feldstein AE. Wree A, et al. Cell Death Differ. 2015 Dec;22(12):1985-94. doi: 10.1038/cdd.2015.46. Epub 2015 Apr 24. Cell Death Differ. 2015. PMID: 25909884 Free PMC article. - Protective effect of salvianolic acid B on NASH rat liver through restoring intestinal mucosal barrier function.
Wang YC, Jin QM, Kong WZ, Chen J. Wang YC, et al. Int J Clin Exp Pathol. 2015 May 1;8(5):5203-9. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26191218 Free PMC article. - The effects of simvastatin-loaded nanoliposomes on human multilineage liver fibrosis microtissue.
Parsa S, Dousti M, Mohammadi N, Abedanzadeh M, Dehdari Ebrahimi N, Dara M, Sani M, Nekouee M, Abolmaali SS, Sani F, Azarpira N. Parsa S, et al. J Cell Mol Med. 2024 Jul;28(13):e18529. doi: 10.1111/jcmm.18529. J Cell Mol Med. 2024. PMID: 38984945 Free PMC article. - Management of hepatocellular carcinoma with portal vein thrombosis.
Quirk M, Kim YH, Saab S, Lee EW. Quirk M, et al. World J Gastroenterol. 2015 Mar 28;21(12):3462-71. doi: 10.3748/wjg.v21.i12.3462. World J Gastroenterol. 2015. PMID: 25834310 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous